Selected article for: "exacerbate disease and immune response"
Author: Callender, Lauren A.; Curran, Michelle; Bates, Stephanie M.; Mairesse, Maelle; Weigandt, Julia; Betts, Catherine J.
Title: The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
  • Cord-id: gbmnoo84
  • Document date: 2020_8_11
    • ID: gbmnoo84
    Snippet: Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myria
    Document: Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.

    Search related documents:
    Co phrase search for related documents
    • absolute number and acute coronary syndrome: 1, 2, 3
    • absolute number and acute kidney injury: 1
    • absolute number and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • ace inhibitor and acei ace inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ace inhibitor and acei arb treatment: 1
    • ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • ace inhibitor and acute coronary syndrome: 1
    • ace inhibitor and acute kidney injury: 1, 2, 3, 4
    • ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor and administration prior: 1
    • acei ace inhibitor and acute respiratory syndrome: 1, 2, 3
    • acei arb treatment and acute ards respiratory distress syndrome: 1
    • acei arb treatment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activator jak signal transducer and acute respiratory syndrome: 1, 2, 3
    • active cancer and acute ards respiratory distress syndrome: 1, 2
    • active cancer and acute kidney injury: 1, 2, 3
    • active cancer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active form and acute ards respiratory distress syndrome: 1
    • active form and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25